- Proteomics has raised $3 million through a heavily oversubscribed share placement
- The company will use its new cash to commercialise its diabetic kidney disease predictor, PromarkerD
- The product boasts the ability to predict diabetic kidney disease up to four years in advance, meaning sufferers can take preemptive steps to minimise kidney damage
- Proteomics shares are trading 4.35 per cent down in early afternoon trade, currently worth 33 cents each
Click here for the entire article on The Market Herald
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
0.005(1.37%) |
Mkt cap ! $60.56M | |||
| Open | High | Low | Value | Volume |
| 36.5¢ | 37.0¢ | 35.0¢ | $51.50K | 144.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 18336 | 36.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 9405 | 1 |
View Market Depth
| Last trade - 15.58pm 30/07/2025 (20 minute delay) ? |
| PIQ (ASX) Chart |